Intestinal microbiota-farnesoid X receptor axis in metabolic diseases

Bu Zou; Wenling Yang; Ying Tang; Yangfeng Hou; Tingting Tang; Shunlin Qu

doi:10.1016/j.cca.2020.06.006

Intestinal microbiota-farnesoid X receptor axis in metabolic diseases

Clin Chim Acta. 2020 Oct:509:167-171. doi: 10.1016/j.cca.2020.06.006. Epub 2020 Jun 4.

Authors

Bu Zou¹, Wenling Yang², Ying Tang¹, Yangfeng Hou¹, Tingting Tang³, Shunlin Qu⁴

Affiliations

¹ Pathophysiology Department, Institute of Cardiovascular Disease, Key Laboratory for Arteriosclerology of Hunan Province, Hunan International Scientific and Technological Cooperation Base of Arteriosclerotic Disease, University of South China, Hengyang City, Hunan Province 421001, PR China; Clinic Department, Hengyang Medical College, University of South China, Hengyang City, Hunan Province 421001, PR China.
² Pathophysiology Department, Institute of Cardiovascular Disease, Key Laboratory for Arteriosclerology of Hunan Province, Hunan International Scientific and Technological Cooperation Base of Arteriosclerotic Disease, University of South China, Hengyang City, Hunan Province 421001, PR China; Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, PR China.
³ Pathophysiology Department, Institute of Cardiovascular Disease, Key Laboratory for Arteriosclerology of Hunan Province, Hunan International Scientific and Technological Cooperation Base of Arteriosclerotic Disease, University of South China, Hengyang City, Hunan Province 421001, PR China.
⁴ Pathophysiology Department, Institute of Cardiovascular Disease, Key Laboratory for Arteriosclerology of Hunan Province, Hunan International Scientific and Technological Cooperation Base of Arteriosclerotic Disease, University of South China, Hengyang City, Hunan Province 421001, PR China. Electronic address: qushunlin78@126.com.

PMID: 32505776
DOI: 10.1016/j.cca.2020.06.006

Abstract

Studies have demonstrated that intestinal microbiota is associated with various metabolic diseases including obesity, nonalcoholic fatty liver, and insulin resistance. Farnesoid X receptor (FXR), also known as the bile acid receptor, belongs to the nuclear receptor superfamily, which is involved in the regulation of bile acid, glucose, and lipid metabolism. Researchers have found that intestinal microbiota can regulate FXR activity by affecting bile acid composition, and then regulate the balance of in vivo metabolism. The intestinal microbiota -FXR axis may be an ideal drug target for metabolic diseases. This review summarizes the latest research on the intestinal microbiota /FXR axis, hoping to provide a theoretical basis for further research and clinical application.

Keywords: Bile salt hydrolase; Farnesoid X receptor; Intestinal microbiota; Metabolic disease; Metformin.

Publication types

Review

MeSH terms

Animals
Bile Acids and Salts
Gastrointestinal Microbiome*
Humans
Metabolic Diseases*
Mice
Mice, Inbred C57BL
Non-alcoholic Fatty Liver Disease*

Substances

Bile Acids and Salts